Arax Advisory Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Arax Advisory Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$804	Buy	476 +469	+6,700%	+$2.06K	﹤0.01%	3341
2025 Q4	$36	Sell	7 -51,352	-100%	-$264K	﹤0.01%	3972
2025 Q3	$268K	Buy	+51,359	New	+$268K	﹤0.01%	1131
2025 Q2	–	Sell	-125	Closed	-$719	–	3035
2025 Q1	$719	Sell	125 -57	-31%	-$337	﹤0.01%	2433
2024 Q4	$909	Sell	182 -84	-32%	-$431	﹤0.01%	2196
2024 Q3	$1.43K	Hold	266	–	–	﹤0.01%	2149
2024 Q2	$881	Buy	+266	New	+$1.04K	﹤0.01%	2207

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arax Advisory Partners's ALDX Position: Q1 2026 in Review

Arax Advisory Partners increased its Aldeyra Therapeutics (ALDX) stake by 6,700% in Q1 2026, buying an estimated $2.06K and bringing the position to 476 shares worth $804. The position accounts for ﹤0.01% of the portfolio, ranked #3341.

Arax Advisory Partners first reported a position in ALDX in Q2 2024 and has held it in 7 quarters since. The position peaked at $268K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Arax Advisory Partners held 476 shares of Aldeyra Therapeutics worth $804 as of Q1 2026.
Arax Advisory Partners bought 469 Aldeyra Therapeutics shares in Q1 2026, an estimated $2.06K.
Aldeyra Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3341 holding.
Arax Advisory Partners first reported a position in Aldeyra Therapeutics in Q2 2024 and has held it in 7 quarters since.
Arax Advisory Partners's Aldeyra Therapeutics position peaked at $268K in Q3 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.